title: Therapy of serious skin and soft tissue infections with ofloxacin administered by intravenous and oral route.
abstract: We evaluated the safety and efficacy of ofloxacin administered both by the intravenous route and orally in 26 men with serious skin and soft tissue infection. Twenty-one patients completed antimicrobial therapy and were fully evaluable. Of these, 18 were judged to be cured, while 3 failed therapy either during or within 2 weeks after completion of therapy. Overall, Staphylococcus aureus was the most commonly isolated pathogen and was found to be susceptible to ofloxacin in 12 of 14 patients. Two patients, 1 with a tolerant isolate of S. aureus, the other patient with a resistant isolate of S. aureus, responded clinically to ofloxacin therapy; a third patient with an initially ofloxacin-sensitive isolate failed therapy, and on subsequent culture an ofloxacin-resistant S. aureus was isolated. Ofloxacin was well tolerated and efficacious in the treatment of skin and soft tissue infections including those caused by staphylococci and streptococci.
authors.affiliation: Medical Service, Edward Hines Jr. VA Hospital, Hines, Ill.
authors.forename: J R
authors.initials: JR
authors.lastname: Lentino
authors.forename: J B
authors.initials: JB
authors.lastname: Augustinsky
authors.forename: T M
authors.initials: TM
authors.lastname: Weber
authors.forename: C T
authors.initials: CT
authors.lastname: Pachucki
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002481:Cellulitis / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D015242:Ofloxacin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction; D012874:Skin Diseases, Infectious / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D015242:Ofloxacin